We report a genome-wide association study for open-angle glaucoma (OAG) blindness using a discovery cohort of 590 individuals with severe visual field loss (cases) and 3,956 controls. We identified associated loci at TMCO1 (rs4656461[G] odds ratio (OR) = 1.68, P = 6.1 × 10 −10 ) and CDKN2B-AS1 (rs4977756[A] OR = 1.50, P = 4.7 × 10 −9 ). We replicated these associations in an independent cohort of cases with advanced OAG (rs4656461 P = 0.010; rs4977756 P = 0.042) and two additional cohorts of less severe OAG (rs4656461 combined discovery and replication P = 6.00 × 10 −14 , OR = 1.51, 95% CI 1.35-1.68; rs4977756 combined P = 1.35 × 10 −14 , OR = 1.39, 95% CI 1.28-1.51). We show retinal expression of genes at both loci in human ocular tissues. We also show that CDKN2A and CDKN2B are upregulated in the retina of a rat model of glaucoma.
Glaucoma is a group of neurodegenerative ocular diseases united by a clinically characteristic optic neuropathy. It is the second leading cause of blindness worldwide 1 . Primary OAG is the commonest glaucoma subtype 1 . OAG pathogenesis and factors determining disease progression are poorly understood. Early intervention with measures to reduce intraocular pressure retards visual loss in most individuals 2 , but many cases of glaucoma remain undiagnosed until after irreversible vision loss. Elucidation of SNPs associated with severe outcomes could enable better targeting of expensive lifelong treatments, with associated morbidity, to individuals with the highest risk of blindness. Linkage and candidate gene studies have identified several genes likely to be involved in OAG including MYOC (encoding myocilin) 3 and NTF4 (ref. 4) , although for the latter, findings have varied in different populations 5 . A recent genome-wide association study (GWAS) using Icelandic cases with OAG of unselected severity identified association with variants near CAV1 (ref. 6 ). To identify genes predisposing individuals to OAG blindness, we performed a GWAS in Australians of European descent with advanced OAG (individuals with OAG who have progressed to severe visual field loss or blindness).
We selected cases with advanced OAG (N = 590 after data cleaning) from the Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG) and the Glaucoma Inheritance Study in Tasmania (GIST) 7, 8 . We used two previously described Australian samples as controls (N = 1,801 and N = 2,155, for a total combined N = 3,956) 9 . Cohort demographics are given in Table 1 , and recruitment and disease definitions are listed in the Supplementary Note. We typed samples on Illumina arrays (we typed cases using Omni1 and controls using HumanHap610 or HumanHap660). We combined cases and controls into a single dataset for cleaning and imputation. All participants were Australians of European descent.
After cleaning, 298,778 SNPs were available for association testing. The genomic inflation factor (λ) in the discovery cohort was 1.06 (quantile-quantile plots uncorrected and corrected for λ are shown in Supplementary Fig. 1a,b) . The λ reduced to 1.04 when we included the first ten principal components as covariates. The association results across the genome are displayed in Figure 1 ; results are presented corrected for λ = 1.06 without correction for principal components. Results with correction for principal components were similar (data not shown). Two regions clearly reached genome-wide significance (defined as P < 5 × 10 −8 ; Table 2) , with P = 6.1 × 10 −10 at rs4656461[G] near TMCO1 on chromosome 1q24 and P = 4.7 × 10 −9 at rs4977756[A] in CDKN2B-AS1 on chromosome 9p21. Association results at these loci for both genotyped and imputed SNPs are shown in Figure 2 . Imputation of SNPs from the 1000 Genomes Project did not reveal any SNPs with substantially Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1 stronger association than the top genotyped SNPs (Fig. 2) or identify additional genome-wide significant loci. At both loci, the most associated SNP is supported by concordant results for other SNPs in moderate or high linkage disequilibrium.
We drew three replication cohorts from the Australian population, and all subjects were of European descent ( Table 1) . The advanced glaucoma replication cohort consisted of 334 additional cases with advanced OAG and 434 controls over 60 years of age (mean age 78.7 years). The less severe cohort consisted of 465 cases with OAG and 1,436 controls from the Wellcome Trust Case Control Cohort 1958 Birth Cohort (WTCCC 58BC). The third cohort was a populationbased study, the Blue Mountains Eye Study, containing 93 cases with glaucoma and 2,712 examined controls. The most-associated SNPs at each locus from the discovery cohort clearly replicated in all replication cohorts ( Table 2) . Other SNPs in both of these regions were also associated in the replication cohorts (Supplementary Table 1a) . Combining all raw data from all replication cohorts in an association analysis gave P = 7.56 × 10 −6 (OR = 1.39, 95% CI 1.20-1.61) for rs4656461 near TMCO1 and P = 4.19 × 10 −7 (OR 1.33, 95% CI 1.19-1.48) at rs4977756 in CDKN2B-AS1 (Supplementary Table 1b) . These SNPs of interest were also still significantly associated with OAG following adjustments for age and sex in a logistic regression analysis (Supplementary Table 1b ), indicating that the observed associations are independent of these parameters despite the differences between the case and control cohorts. We combined all available controls to enable a comparison of ORs for the risk alleles at both loci between the advanced OAG cohorts and the less severe OAG cases (Supplementary Table 1c) . We observed stronger ORs in the advanced cases, and these results support the hypothesis that the risk alleles identified are associated with OAG in general but are more strongly associated with cases which progress to advanced disease. Alternatively, higher diagnostic certainty in severe disease could account for this observation.
Combining raw data from the discovery and all replication cohorts in a study-wide association analysis generated an overall OR = 1.51 (95% CI 1.35-1.68) and P = 6.0 × 10 −14 for rs4656461 and OR = 1.39 (95% CI 1.28-1.51) and P = 1.35 × 10 −14 for rs4977756 ( Table 2) . Haplotype analyses indicated three common haplotypes around TMCO1 and two at CDKN2B-AS1. The overall P values for association were P = 6.56 × 10 −12 around TMCO1 and P = 2.59 × 10 −9 at the CDKN2B-AS1 locus (Supplementary Table 2 ). In both cases, the risk alleles detected in the single SNP analysis are present on a single common haplotype that shows significant association with OAG. The haplotype with the alternative allele at each location appears to be protective against developing OAG. We sequenced 12 individuals with OAG who were homozygous for the risk allele at rs4656461 at all coding exons of TMCO1 and the 3′ untranslated region (UTR). We found several common SNPs in the 3′ UTR to be present on the risk haplotype, although the functionality of these SNPs is not known (Supplementary Table 3) . The lack of identified coding variants suggests the true causative variants are likely to be located in a regulatory region of TMCO1.
We used two control cohorts in this study; one population sample based on parents of twins and the other a sample of individuals with endometriosis. We subjected cases and controls to the same cleaning regime to ensure a well-matched dataset. The male to female ratio was similar between the case cohort and the twin-based controls, but the endometriosis controls were all female. We repeated the association analysis excluding the endometriosis controls, and this generated P values at rs4656461 and rs4977756 of P = 5.3 × 10 −9 and P = 1.1 × 10 −7 , respectively. The reduced significance level of this association can be explained by the smaller sample size, as allele frequencies were very similar between control cohorts (Supplementary Table 4a ). In addition, we utilized the WTCCC 58BC data as an alternative control cohort for the discovery analysis. The top SNPs at both loci were associated with genome-wide significance levels in this analysis, indicating that our findings do not represent an artifact of the historic controls used (Supplementary Table 4b and Supplementary Fig. 1c) .
To obtain an unbiased estimate of risk for advanced glaucoma, we focused on the first replication cohort 10 . Taking the cases with advanced glaucoma (N = 334), the matched examined elderly controls (N = 434) and similar age-matched controls from the Blue Mountains Eye Study cohort (N = 502), we fitted rs4977756 and rs4656461 into a logistic regression model. Assuming an additive model, individuals carrying four risk alleles (two at each locus) had a 4.50-fold (95% CI 1.84-11.01) higher risk of advanced OAG relative to non-carriers. Grouping individuals with one or two risk alleles together at both loci (dominant model) gave a 3.03-fold (95% CI 1.52-6.07) increased risk. Eighteen percent of the population are in this risk category. l e t t e r s l e t t e r s rs4656461 at the 1q24 locus is ~6.5 kb downstream of TMCO1. rs4977756 at the 9p21 locus is located within the antisense RNA gene CDKN2B-AS1. This region also harbors the tumor suppressor genes CDKN2A and CDKN2B and is adjacent to MTAP. CDKN2A also encodes an alternate open reading frame, known as ARF. We analyzed expression of these genes in human ocular tissues by RT-PCR. All the genes are expressed in the iris, ciliary body, retina and optic nerve, but the expression levels varied among the tissues analyzed (Fig. 3a) . Furthermore, we determined which of the CDKN2B-AS1 splice variants were expressed in the retina, the tissue that is ultimately compromised in glaucoma. RT-PCR revealed expression of three splice variants of this gene in the human retina (Fig. 3b) . This is consistent with expression of more than one CDKN2B-AS1 splice variants in a tissue or cell line 11, 12 . We used well-characterized antibodies directed against Cdkn2a, Cdkn2b, Mtap and Tmco1 to explore the distribution of these proteins in rat retina. Cdkn2a and Cdkn2b were expressed in retinal ganglion Figure 2 Association results for SNPs at the genome-wide significant loci corrected for λ = 1.06. Genotyped SNPs are indicated by solid triangles, and imputed SNPs are indicated by hollow circles. The top ranked SNP at each locus is shown as a solid diamond. Imputation P values for all SNPs are plotted. The color scheme indicates linkage disequilibrium between the top ranked SNP and other SNPs in the region. Note that the imputed and genotyped P values for genotyped SNPs differ slightly because for the imputed result, the analysis was based on dosage scores, whereas with genotyped SNPs, the hard genotype calls are used. (a) Chromosome 1q24 region. The imputation P value was P = 1.0 × 10 −9 for the top SNP, rs7524755, with the top genotyped SNP, rs4656461, the fourth best SNP after imputation, with P = 1.6 × 10 −9 . (b) Chromosome 9p21 region. The imputation P value was P = 3.7 × 10 −9 for the top SNP, rs10757270, with the top genotyped SNP, rs4977756, the second best SNP after imputation, with P = 8.1 × 10 −9 .
l e t t e r s cells (RGC) and other retinal cell types with nuclear patterns of localization, similar to the patterns reported in other tissues ( Supplementary  Fig. 2 ). Tmco1 was also associated with all retinal cells, but we observed the strongest expression in RGC. Mtap was expressed at low levels in retinal astrocytes (data not shown). To determine whether these genes are candidates for involvement in the pathogenesis of glaucoma, we performed real-time PCR analysis of their expression levels in a validated rat model of glaucoma 13 (Fig. 4) . We observed strong upregulation of expression of Cdkn2a and Cdkn2b, but not Tmco1, in the retina one week after induction of ocular hypertension, a time point corresponding to ongoing RGC death, as indicated by axonal cytoskeleton damage in the optic nerve of the animals studied.
Recessive mutations in TMCO1 cause a syndrome consisting of craniofacial dysmorphism, skeletal anomalies and mental retardation 14 . The gene encodes a transmembrane protein with a coiled-coil domain that may localize to the Golgi apparatus and endoplasmic reticulum 15 or to the mitochondria 16 in different cell types. In humans, the gene is ubiquitously expressed in developing and adult tissues 14 . The protein sequence is completely conserved among many mammalian species 14 . Although requiring experimental confirmation, researchers in a previous study proposed a role for TMCO1 in apoptosis 16 . This may suggest a mechanism for the association with glaucoma, which is characterized by excessive RGC apoptosis. It is also possible that other genes adjacent to TMCO1, such as ALDH9A1, could be responsible for the glaucoma association observed in this study.
CDKN2B-AS1 resides in the 9p21 region that has been clearly associated with cardiovascular disease 17 , diabetes 18 , intracranial aneurysm 19 and glioma 20 . The antisense RNA encoded by CDKN2B-AS1 regulates neighboring genes at 9p21, particularly CDKN2B, with which its expression levels are reciprocally related 21 . CDKN2B and CDKN2A activate the retinoblastoma tumor suppressor pathway, whereas ARF activates the p53 tumor suppressor pathway. The 9p21 locus is activated in response to oncogenic stimuli 22 . CAV1, recently reported to be associated with OAG 6 , regulates mitogenic signaling and acts synergistically with CDKN2A (ref. 23) . Although the CAV1 SNP (rs4236601) did not reach statistical significance in this GWAS (P = 0.17 for a one-sided test), the observed odds ratio of 1.07 is consistent with that previously reported in larger European cohorts, as are the allele frequencies (cases, 0.290; controls, 0.276 for the A allele). It should be noted that many of the cases in the current study are included in the previously reported Australian replication cohort 6 . Genes at the 9p21 locus are known to play a role in aberrant cell division, and we propose that the 9p21 OAG risk variants may predispose RGCs to gradual apoptosis. This hypothesis is supported by observations that the opposite risk alleles in CDKN2B-AS1 are associated with glaucoma and glioma. For example, at rs4977756 and rs1063192, the G and C alleles, respectively, are protective for glaucoma but are the risk alleles for glioma 20 . The direction of association is the same for glaucoma as for cardiovascular disease 17 and diabetes 18 , but further work is required to determine whether the same causative variant(s) underlie these different disease associations.
Recently, rs1063192 in CDKN2B was reported to be associated at genome-wide significance with optic cup to disc ratio in healthy individuals 24 . Nominal association of this SNP with glaucoma in a small case series was also reported 24 . In our study, this particular SNP had P = 3.9 × 10 −7 in the discovery cohort, and the nearby SNPs in CDKN2B-AS1 reached genome-wide significance. Thus, we provide further compelling evidence that the 9p21 region is a strong genetic risk factor for OAG in support of the previous suggestive association with OAG at this locus.
This study shows evidence of association of two candidate genes, TMCO1 and CDKN2B-AS1, with advanced OAG, imparting a threefold increase in risk for carriers of one or more risk alleles at the two loci. 11, 12 . The full-length variant (DQ485453) and alternatively spliced variants (DQ485454 and GQ495924) 11, 12 were undetectable in human retina (data not shown). M, molecular weight markers in base pairs; RT − , reverse transcription negative control; −ve C, PCR negative control. In addition, we have shown strong upregulation of CDKN2A and CDKN2B in response to elevated intraocular pressure, further indicating that this region is important in the molecular pathways leading to glaucoma development. This discovery was made utilizing an approach of selecting cases with severe blinding OAG for the GWAS, but as expected, the risk alleles are also associated with less severe cases, showing the efficacy of using extreme cases to identify genes for a common disease. OAG can be difficult to diagnose in the early stages, and these findings may be useful in the future to prioritize treatment effectively for individuals with possible but not definite early glaucoma (glaucoma suspects), for whom it is often difficult to decide upon the timing of treatment initiation. As treatment for glaucoma is proven to slow disease progression 2 , timely initiation of conventional treatment in those individuals at the highest risk could reduce glaucoma blindness. In addition, we have highlighted biochemical pathways involved in this disease, which could lead to more targeted OAG treatment regimes aiming to protect RGC in ways other than lowering intraocular pressure which has until now formed the cornerstone of treatment. 
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Cohort descriptions. See Supplementary Note.
Genotyping and data quality control. Following DNA extraction, Australian twin and endometriosis sample controls were genotyped at deCODE Genetics (Reykjavik, Iceland) on Illumina HumanHap 610W Quad and Illumina Human670Quad Bead arrays, respectively. Cases were genotyped in the laboratory of M.A.B. on Illumina Human1M-Omni arrays. SNPs with a mean BeadStudio GenCall score <0.7 were excluded from the controls. All samples had successful genotypes for >95% of SNPs. SNPs with call rates either <0.95 (minor allele frequency (MAF) > 0.05) or <0.99 (MAF > 0.01), Hardy-Weinberg equilibrium in controls P < 10 −6 and/or MAF < 0.01 were excluded. Cryptic relatedness was identified through the production of a full identity by state matrix, and 0 cases and 72 controls were removed. Ancestry outliers were identified by principal component (PC) analysis using data from 11 populations of the HapMap 3 and 5 Northern European populations genotyped by the GenomeEUtwin consortium using the EIGENSOFT package 25 and a subset of 160,000 independent SNPs. Individuals (n = 25 cases and 219 controls) lying ≥2 standard deviations from the mean PC1 and PC2 scores were removed. Following these exclusions, there were 590 cases genotyped for 790,038 SNPs and 3,956 controls genotyped for 518,687 SNPs. Our primary analysis was based on a common set of 298,778 SNPs. To investigate population stratification in the cleaned dataset, we generated quantile-quantile plots. These same SNPs were used to generate the first ten principal components for case and control samples combined using EIGENSOFT.
Genomic imputation. Imputation for the Australian twins was performed using MACH2 with data obtained by the Centre d'Etude du Polymorphisme Humain from the 1000 Genomes reference panel 2010_03 release. Imputation was based on a set of autosomal SNPs common to all samples (n = 292,883). The total number of SNPs imputed with imputation r 2 > 0.5 was 5,548,553, and these SNPs were taken forward for analysis.
Association analysis. Association analysis was performed using PLINK 26 . Dosage scores from imputation analysis were obtained using MACH2DAT 27 . The analysis was conducted with and without the first ten principal components included as covariates (with negligible difference to results, data not shown). Figure 2 was prepared using LocusZoom 28 .
Replication study genotyping and analysis. All genome-wide significant SNPs were further examined in an independent replication, along with additional SNPs at each locus. SNPs chosen for genotyping were those mapping to each locus defined as within the annotated genes TMCO1 (four SNPs), CDKN2A (two SNPs), CDKN2B (two SNPs) or CDKN2B-AS1 (five SNPS) and ranked within the top 1,000 genotyped SNPs. In addition, SNPs previously reported as associated with other phenotypes at the 9p21 locus but not typed in the discovery phase were also included if the assay design allowed them to multiplex with the other SNPs (four SNPs). SNPs were genotyped using iPLEX Gold chemistry (Sequenom Inc.) in a single plex on an Autoflex Mass Spectrometer (Sequenom Inc.) at the Australian Genome Research Facility (Brisbane, Australia). Genotypes for controls from the BMES cohort were extracted from a previously conducted genome-wide association scan using Illumina HumanHap 670 arrays. Genotypes of the WTCCC 58BC cohort typed on the Illumina HumanHap550 array were downloaded from the European Genome-phenome Archive, and the relevant SNPs were extracted. Each SNP in the replication phase was checked for consistent strand and flipped in one dataset if necessary. The association analysis was conducted in PLINK. Advanced replication cases were compared to 434 elderly examined controls. We compared 465 less severe cases to the WTCCC 58BC data (n = 1,436), and glaucoma cases from within the BMES (n = 93) were analyzed compared to all other participants with available genotype data (n = 2,712). Raw data were pooled for the combined replication cohort analysis and the combined study (discovery and replication cohorts) analysis. An analysis was conducted as for each individual cohort using PLINK. Age and sex were included in a logistic regression analysis under an additive model.
Haplotype analysis. The haplotype analysis was conducted on the combined dataset of all cases, the discovery controls and a subset of BMES controls that were genotyped in house. Analysis was conducted in PLINK. All four TMCO1 SNPs from the replication phase were included in the haplotype. Prior to analysis, the chromosome 9 locus was assessed in this data for linkage disequilibrium structure using Haploview 29 . The 'solid spine of LD' block definition was used, and this definition identified a block between rs3217992 and rs4977756, and haplotypes were calculated in this block. Inclusion of SNPs outside this block resulted in a large number of rare and less common haplotypes. Only haplotypes with frequency >1% were considered.
Re-sequencing. The coding exons, 3′ UTR and all splice sites of TMCO1 were sequenced in 12 cases who were homozygous for the risk allele (G) at rs4656461. Primers are given in Supplementary Immunohistochemistry in rat ocular tissue. Tissue sections were deparaffinized in xylene and rinsed in 100% ethanol before treatment with 0.5% H 2 O 2 for 30 min to block endogenous peroxidase activity. Antigen retrieval was achieved by microwaving the sections in 10 mM citrate buffer (pH 6.0). Tissue sections were then blocked in 3% normal horse serum made in phosphate buffered saline (PBS), incubated overnight at room temperature (20-25 °C) in primary antibody followed by consecutive incubations with biotinylated secondary antibody (Vector) and streptavidin-peroxidase conjugate (Pierce). Color development was achieved with NovaRED (Vector). Sections were counterstained with hematoxylin, dehydrated and mounted. Specificity of antibody staining was confirmed by incubating adjacent sections with mouse IgG1 isotype control (BD Pharmingen) or normal rabbit serum for the monoclonal antibody and polyclonal rabbit antibodies, respectively. The primary antibodies used were anti-mouse CDKN2A (Abcam, clone 2D9A12, 1:1000), CDKN2B (Cell Signaling Technology, #4822, 1:1000) and anti-rabbit TMCO1 (Aviva Systems Biology, ARP49429_P050, 1:500 to 1:1,000). For protein blotting to confirm specificity of the TMCO1 antibody, samples from rat liver, brain, retina and optic nerve were sonicated in freshly prepared 20 mM Tris.HCl buffer (pH 7.4) containing 2 mM EDTA, 0.5 mM EGTA, the protease inhibitors phenylmethyl-sulfonyl fluoride (0.1 mM), leupeptin (50 µg/ml) and aprotinin (50 µg/ml) plus a phosphatase inhibitor cocktail. An equal volume of sample buffer (62.5 mM Tris plus HCl, pH 7.4, 4% SDS, 10% glycerol, 10% β-mercaptoethanol and 0.002% bromophenol blue) was added and samples were boiled for 3 min. Samples were size fractionated by SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membrane. The blot was blocked with 5% skimmed milk and Tris buffered saline containing 0.1% Tween 20, probed with antibodies to actin or TMCO1 followed by appropriate secondary antibodies conjugated to biotin and then streptavidin-peroxidase conjugate. The blot was developed with a 0.016% solution of 3-amino-9-ethylcarbazole in 50 mM sodium acetate (pH 5) containing 0.05% Tween-20 and 0.03% H 2 O 2 .
Evaluation of gene expression levels in a rat model of glaucoma. SpragueDawley rats were anesthetized with an intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg xylazine, and local anesthetic drops were applied to the eye. Ocular hypertension was induced in the right eye of each animal by laser photocoagulation of the trabecular meshwork as previously described 13 . Intraocular pressures were measured in both eyes at baseline, at 8 h and at days 1, 3 and 7 using a rebound tonometer calibrated for use in rats. All rats were killed by transcardial perfusion with physiological saline under deep anesthesia. The retinas were dissected for RT-PCR, and the chiasm from each rat was taken for immunohistochemistry to verify that the procedure had induced an appropriate injury response using the same method detailed above. Total RNA was isolated from each retina, and first strand cDNA was synthesized from 2 µg DNase-treated RNA. Duplicate real-time PCR reactions were carried out using the cDNA equivalent of 20 ng total RNA for each sample in a total volume of 25 µl containing 1× SYBR Green PCR master mix (BioRad) in an IQ5 icycler (Bio-Rad). The primer sets used are detailed in Supplementary Table 5 . After the final cycle of the PCR, primer specificity was checked by the dissociation (melting) curve method. The relative expression in each sample was calculated using Gapdh as reference mRNA as previously described 31 .
